TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
TRACON Pharmaceuticals Announces Reverse Stock Split
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) had its price target lowered by analysts at HC Wainwright from $6.00 to $3.00. They now have a "buy" rating on the stock.
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned [Yahoo! Finance]